Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada
Public And Private Listings For Reimbursement Are In The Works
Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.
You may also be interested in...
Celltrion Bags FDA Approval For High-Concentration Humira Rival
Celltrion has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
Hikma Strikes Deal For Celltrion’s Yuflyma
Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.
Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar
Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.